The present study will administer the drug leronlimab to 20 participants who are above 50 years old with Alzheimer's disease (AD) or mild cognitive impairment (MCI) due to AD. While leronlimab is considered safe in other diseases like Human Immunodeficiency Virus (HIV) and certain types of cancer, its safety and tolerability in AD will be tested for the first time. The main purpose of this study is to learn:
1. Is this drug safe for participants with AD and MCI due to AD?
2. Does leronlimab change levels of brain inflammation?
The results of this study could lead to future studies with more participants that will test whether leronlimab may slow or prevent the decline in thinking abilities and brain function in this group of participants. Using leronlimab for Alzheimer's disease is experimental, which means that the Food and Drug Administration (FDA) has not approved leronlimab for this purpose.
Participants will be asked to take leronlimab once a week for 12 weeks in our clinic or in their own home. Participants will also be asked to complete the below procedures before and after taking leronlimab for 12 weeks:
1. Undergo 2 types of brain scans, Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI).
2. Visit our clinic for routine lab work, an electrocardiogram (ECG), and a physical exam.
3. Donate blood so the researchers can better understand how leronlimab affects levels of inflammation and proteins related to AD in the blood.
4. Undergo a series of tests and questionnaires that test thinking abilities.
5. Have weekly phone calls with researchers to let them know if there are side effects while taking this drug.

Start Date30 Apr 2026

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT06699836

/ Active, not recruitingPhase 2

A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)

This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are:
1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in persons with MSS, mCRC who have progressed on prior treatment before participating in the study.
2. Is leronlimab safe and well tolerated in these subjects when used in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab.

Start Date16 Jun 2025

Sponsor / Collaborator

CytoDyn, Inc.

[+1]

NCT05730673

/ WithdrawnPhase 2

A Phase II Study of Leronlimab (PRO 140) in Combination With Regorafenib in Patients With CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

This is aPhase II Study of Leronlimab (PRO 140) in combination with Regorafenib in Patients with CCR5+, Microsatellite Stable (MSS), Metastatic Colorectal Cancer (mCRC)

Start Date20 Sep 2022

Sponsor / Collaborator

CytoDyn, Inc.

[+1]

100 Clinical Results associated with Leronlimab

100 Translational Medicine associated with Leronlimab

100 Patents (Medical) associated with Leronlimab

Literatures (Medical) associated with Leronlimab

01 Jul 2026·LIFE SCIENCES

Omega-3 modulates macrophage immunometabolic profile without changing Pseudomonas aeruginosa proliferation

Article

Author: Corsetti, Patrícia Paiva ; Miranda, Tatiana Teixeira de ; de Araújo, Leonardo Pereira ; Moreira, Ana Clara ; Fagundes, Caio Tavares ; Braida, Yasmin Vieira ; Carneiro, Fernanda Silva ; Silva, Evandro Neves ; Sousa, Lirlândia Pires de ; de Almeida, Leonardo Augusto ; Sousa, Priscila Vilela

The increasing and often indiscriminate use of medications challenges populations with limited access to effective treatments. Natural compounds such as omega-3 fatty acids (FA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert immunomodulatory effects by incorporating into macrophage membranes and modulating cytokine production and metabolism. This study evaluated the effects of omega-3 FA on inflammatory responses, metabolic reprogramming, and signaling pathways in bone marrow-derived macrophages (BMDMs) infected with Pseudomonas aeruginosa. BMDMs from C57BL/6 mice were pretreated for 3 h with 26 mg DHA and 36 mg EPA, then stimulated with P. aeruginosa (PA14), heat-killed bacteria (HKPA), or lipopolysaccharide (LPS). Omega-3 FA pretreatment reduced pro-inflammatory mediators, including TNF-α, IL-1β, nitric oxide, and NLRP3 expression in macrophages stimulated with PA14, HKPA and LPS, while IL-10 secretion was also reduced under these stimuli. However, omega-3 FA increased IL-10 production under basal conditions. Gene expression analysis revealed upregulation of M2-associated markers (ARG1 and CD206), without changes in the M1 marker iNOS. Metabolic and transcriptional analyses demonstrated downregulation of glycolysis-related genes and upregulation of genes associated with mitochondrial function and lipid metabolism. Omega-3 FA did not alter P. aeruginosa proliferation but increased bacteria phagocytosis. Molecular docking suggested that omega-3 FA interact with key inflammatory targets, including GPR120 and PPARγ. Consistently, pharmacological antagonism of PPARγ reversed the omega-3 FA suppressive effects on TNF-α and IL-1β production and NLRP3 expression. These results indicate that omega-3 FA modulates macrophage immune responses and metabolism during P. aeruginosa infection, promoting an anti-inflammatory, metabolically adapted phenotype without impairing bacterial clearance.

01 Jul 2026·BIOCHIMIE

Effects of head group substitution on large antiviral polyamide-DNA binding kinetics

Article

Author: Fisher, Chris ; Koeller, Kevin J ; Song, Yang ; Niederschulte, Jacquelyn ; Edwards, Terri G ; Dupureur, Cynthia M ; Bashkin, James K ; Harris, G Davis

Hairpin polyamides are pyrrole-based polymers that bind in the minor groove of DNA with remarkable affinity and specificity. While the natural product netropsin that inspired PA design features a terminal guanidinium group, few studies have examined how the head groups affect PA-DNA binding behavior and biological activity. Here the effects of two headgroup substitutions on DNA binding and antiviral behavior are explored with two large (14- and 20-ring) hairpin polyamides. To complete two sets of three polyamides, the syntheses of two, 20-ring hairpin polyamides with N-terminal cationic substitutions (guanidinium (Guan) and tetramethyl guanidine (TMG)) are reported. Using a fluorescence binding assay, some small differences in binding affinity toward a small DNA hairpin are observed for the PA14 series, with head-group substitution weakening low-nM binding by at least several-fold. DNA binding kinetics for head group-substituted PA14 exhibit biphasic traces. The head groups have no effect on a diffusion-controlled binding event, but result in a newly observed, concentration-independent slower phase. In contrast, head group substitutions significantly weaken DNA binding for PA20, and in the case of PA20-Guan, by 1000-fold. Head group substitution results in a faster first binding event for PA20, and a newly detected, second, slower binding event. Head group substitutions do not significantly alter dissociation decay constants for the PA14 series, with little effect across the PA20 series. Perturbations in pM to low nM PA-DNA binding affinities have little to no impact on μM IC₅₀ and IC₉₀ values. However there is a positive correlation between long residence times and antiviral behavior.

29 Apr 2026·Science Translational Medicine

Adeno-associated virus gene therapy-mediated CCR5 blockade suppresses virus replication long term in SHIV-infected macaques.

Article

Author: Crank, Hugh ; Swanson, Tonya ; Hull, Joshua A ; Fuchs, Sebastian P ; Fisher, Hannah K ; Smedley, Jeremy V ; Pessoa, Cleiton T ; Desrosiers, Ronald C ; Bailey, Lauren ; Webb, Gabriela M ; Elmore, Zachary C ; Barber-Axthelm, Aaron ; Sacha, Jonah B ; Wu, Helen L ; Brown, Mischa K ; Chun, Kimberly ; Magnani, Diogo M ; Fennessey, Christine M ; Devlin, Garth ; Axthelm, Michael K ; Fischer, Miranda ; Potter, Sofia K ; Humkey, Matthew C ; Asokan, Aravind ; Hwang, Joseph M ; Boyle, Carla D ; Keele, Brandon F ; McCullen, Allyson J ; Waytashek, Courtney M ; White, Riely ; Kukula, Kaitlyn A ; Zikos, Joanna ; Armantrout, Kimberly

Adeno-associated virus (AAV) vectors are promising vehicles for the delivery and long-term expression of antibodies for treatment of chronic diseases. Given the strong link between the C-C chemokine receptor 5 (CCR5)-Δ32/Δ32 genotype and protection from HIV, we explored the ability of AAV vectors expressing the CCR5-blocking antibody leronlimab to mediate a functional cure in simian-human immunodeficiency virus (SHIV)-infected rhesus macaques by interrupting viral access to the viral entry co-receptor CCR5. Delivery of AAV-leronlimab to rhesus macaques elicited antidrug antibodies (ADA) and rapid plasma leronlimab clearance in approximately half of the treated macaques. However, in these same animals, we observed spontaneous leronlimab transgene reemergence and detectable CCR5 receptor occupancy approximately 1 year later that subsequently persisted indefinitely without rebound of ADA. In macaques that did not mount robust ADA responses, detectable plasma leronlimab concentrations and CCR5 receptor occupancy were maintained for more than 1 year. Of the nine macaques producing sufficient leronlimab to achieve full CCR5 receptor occupancy on blood CD4⁺ T cells, AAV-leronlimab drove stringent or partial control of SHIV viremia in six macaques long term. In the three macaques with uncontrolled SHIV viremia, short-term administration of exogenous leronlimab induced complete SHIV suppression in two and a 100-fold reduction in the third, indicating that a threshold of leronlimab expression is necessary to effectively halt SHIV replication. These results demonstrate the potential of gene therapy-mediated long-term antibody-based CCR5 blockade for HIV functional cure but highlight challenges in achieving sufficient antibody expression when targeting an abundant self-antigen.

175

News (Medical) associated with Leronlimab

16 Jun 2026

·www.biospace.com

CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease

Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease VANCOUVER, Washington, June 11, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple therapeutic indications, today announced that the first patient has been dosed in a Phase 2a clinical study evaluating leronlimab in patients with Alzheimer’s disease, in collaboration with Weill Cornell Medicine. The study, known as SALIENT-AD (Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer’s Disease), is a Phase 2a, open-label, proof-of-concept study designed to evaluate the safety and biological activity of leronlimab in approximately 10 to 20 patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease. Patients will receive weekly subcutaneous injections of leronlimab over a 12-week treatment period. The primary endpoint will assess changes in brain inflammation and microglial activation using advanced PET imaging techniques. Secondary endpoints include safety and tolerability, cognitive assessments, blood-based biomarkers of inflammation and neurodegeneration, and measures of blood-brain barrier integrity using MRI. The study will be led by Tracy Butler, MD, Associate Professor of Neurology in Radiology and Psychiatry and Medical Director of the Brain Health Imaging Institute at Weill Cornell Medicine. “This study is designed to evaluate whether modulation of CCR5 can meaningfully impact neuroinflammatory processes that are increasingly recognized as central to Alzheimer’s disease,” said Dr. Butler. “We are leveraging advanced imaging and biomarker tools to better understand how targeting immune signaling pathways may influence disease biology.” “While CytoDyn remains focused on developing leronlimab in oncology, and we are especially encouraged by the early readouts from our CLOVER Phase 2 study in patients with mCRC, the collaboration with Weill Cornell Medicine in the SALIENT-AD study represents an opportunity to explore potential patient benefit in an indication that represents a significant unmet need,” said Jacob Lalezari, M.D., chief executive officer, CytoDyn. Alzheimer’s disease is a complex and multifactorial neurodegenerative condition characterized not only by amyloid-beta plaques and tau tangles, but also by chronic neuroinflammation, microglial activation, and disruption of the blood-brain barrier. Emerging research suggests that CCR5, a chemokine receptor expressed on immune cells, may play a central role in regulating these processes. Preclinical and translational research suggests that CCR5 plays a role in synaptic plasticity, memory formation, and microglial signaling, and may influence processes such as autophagy, vascular health, and blood-brain barrier stability. By blocking CCR5, leronlimab may help reduce maladaptive immune signaling and support neuronal resilience. About CytoDyn CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide. For more information, please visit and follow us on LinkedIn . Note Regarding Forward-Looking Statements This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law. Corporate Contact CytoDyn Inc. ir@cytodyn.com Media Contacts David Schull or Ignacio Guerrero-Ros, Ph.D. Russo Partners, LLC CytoDyn@russopartnersllc.com

Phase 2

04 Jun 2026

·www.biospace.com

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer

AUSTIN, Texas & VANCOUVER, Wash.--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics and generate real-world molecular insights to support CytoDyn’s metastatic colorectal cancer (mCRC) development program. Under the agreement, Natera will assess CytoDyn clinical trial samples from the CLOVER Phase 2 study (ClinicalTrials.gov Identifier: NCT06699836 ) in patients with mCRC. Signatera TM , Natera’s personalized assay for the detection of molecular residual disease (MRD), will be used to evaluate ctDNA dynamics and molecular response patterns associated with leronlimab treatment. Natera will also provide customized real-world data (RWD) analyses leveraging its proprietary oncology database, which is the largest multi-timepoint early- and late-stage oncology dataset with more than 2 million plasma timepoints and enriched clinical and imaging records. By integrating molecular response data from its MRD testing platform with curated electronic medical record (EMR) data, this multimodal dataset enables analyses of patient populations, treatment patterns, ctDNA response rates, and response dynamics across diverse clinical settings. Together, these capabilities are expected to generate insights into molecular response and disease progression that may help inform future clinical development of leronlimab, including clinical trial design, biomarker-driven patient selection strategies, and broader translational research efforts. The collaboration builds on CytoDyn’s growing oncology program and follows completion of enrollment in the CLOVER study, which is evaluating leronlimab in combination with trifluridine/tipiracil (TAS-102) and bevacizumab in patients with previously treated mCRC. The collaboration is also expected to complement ongoing translational and biomarker analyses from the study aimed at further characterizing treatment response and informing future development strategies. “Signatera has become an increasingly important tool in precision oncology and clinical development,” said Jacob Lalezari, M.D., chief executive officer, CytoDyn. “Through this collaboration, we expect to gain valuable insights into ctDNA response kinetics and disease progression that may help guide future development strategies for leronlimab in colorectal cancer and potentially other solid tumor indications.” “We are pleased to partner with CytoDyn and provide their team with insights derived from one of the largest and most comprehensive real-world molecular oncology data platforms,” said Matt Love, vice president, biopharma data & AI partnering, Natera. “Our platform enables biopharma partners to better understand disease biology, treatment response, and patient outcomes, helping inform key development decisions throughout the drug development lifecycle.” About Natera Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit . About CytoDyn CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide. For more information, please visit and follow us on LinkedIn . Forward-Looking Statements (for Natera) All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our or our partners’ efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at and . Forward-Looking Statements (for CytoDyn) This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law. Contacts Contacts (for Natera) Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com Contacts (for CytoDyn) Corporate Contact: CytoDyn Inc., ir@cytodyn.com Media: David Schull or Ignacio Guerrero-Ros, Ph.D.; Russo Partners, LLC, CytoDyn@russopartnersllc.com

Phase 2License out/in

20 May 2026

·www.prnewswire.com

CREATV BIO STUDIES PRESENTED AT AACR ANNUAL MEETING SHOWING IMPORTANCE OF MONITORING PD-L1, MITOTIC CTCs and CAMLs IN BLOOD

MONMOUTH JUNCTION, N.J., May 20, 2026 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, presented five posters in conjunction with several research collaborators at the 2026 AACR Annual Meeting, held in San Diego, CA. 1. Mitosis in circulating tumor cells correlates with highly aggressive disease in metastatic breast cancer Abstract: 1065 Key Finding: Circulating tumor cells (CTCs) undergoing mitosis is indicative of highly aggressive disease with poor survival rates. 2. Monitoring PD-L1 in tumor macrophage fusion cells in blood correlates to PD-L1 checkpoint inhibitor responses in metastatic breast cancer Abstract: 1025 Key Finding: Monitoring PD-L1 in tumor macrophage fusion cells (TMFCs) serves as a real-time blood biomarker that predicts Immune Checkpoint Inhibitor (ICI) responses in metastatic breast cancer. 3. Combining circulating tumor cells and cancer associated macrophage-like cells enhances risk stratification models in pan-cancer metastatic disease Abstract: 1068 Key Finding: Cancer associated macrophage-like cells (CAMLs) are a subtype of TMFCs. Simultaneous quantification of both CTCs and CAMLs allows for more accurate patient risk stratification. 4. Leronlimab induces PD-L1 expression and is associated with long term survival with an ICI in PD-L1 low metastatic TNBC Abstract: 1033 Key Finding: Monitoring PD-L1 expression on CTCs and CAMLs identifies PD-L1 upregulation after treatment with leronlimab. 5. Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer Abstract: 6466 Key Finding: Monitoring CTCs, CAMLs and ctDNA show promise as early assessments for clinical response when treated with leronlimab. Creatv's LifeTracDx® blood test utilized CellSieve microfilters to isolate, collect and measure both CTCs and CAMLs (number and size) in each of the clinical studies above. About Creatv Bio Creatv Bio operates a CLIA-certified cancer diagnostics laboratory, supporting its pharmaceutical partners with research and investigational studies. Creatv's LifeTracDx® blood test is an analytically validated assay used for research and development. Current applications include evaluation of circulating biomarkers supporting translational and exploratory studies. The assay is intended for research and investigational use only and is not for use in clinical diagnosis, prognosis, treatment selection, or disease monitoring. Creatv contacts (creatvbio.com): SOURCE Creatv MicroTech, Inc. 21% more press release views with Request a Demo

100 Deals associated with Leronlimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11399	Leronlimab	-	DB05941

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	NDA/BLA	United States	CytoDyn, Inc.	01 Nov 2021
COVID-19	Phase 3	United States	CytoDyn, Inc.	05 Aug 2020
Alzheimer Disease	Phase 2	United States	Weill Medical College of Cornell University	30 Apr 2026
Encephalitis	Phase 2	United States	Weill Medical College of Cornell University	30 Apr 2026
Neuroinflammation	Phase 2	United States	Weill Medical College of Cornell University	30 Apr 2026
pMMR/MSS/MSI-L Colon Cancer	Phase 2	United States	CytoDyn, Inc.	16 Jun 2025
Unresectable Colorectal Carcinoma	Phase 2	United States	CytoDyn, Inc.	16 Jun 2025
Metastatic Colorectal Carcinoma	Phase 2	-	CytoDyn, Inc.	20 Sep 2022
Metastatic Microsatellite Stable Colorectal Carcinoma	Phase 2	-	CytoDyn, Inc.	20 Sep 2022
MSS/pMMR/MSI-L Colorectal Carcinoma	Phase 2	-	CytoDyn, Inc.	20 Sep 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03838367 (ASCO2026)	Phase 1/2	Metastatic Triple-Negative Breast Carcinoma C-C chemokine receptor 5 (CCR5) \| PD-L1 low/negative	28	Leronlimab plus physician’s choice combination therapy	ggxulaczux(mngzpaaeaz) = 10.7% bhaejyjpjt (fpsclhxbzd ) View more	Positive	29 May 2026
NCT02859961 (CTgov)	Phase 2/3	HIV Infections	562	PRO 140 (Part 1 - 350 mg Weekly Injections of PRO 140, Group A)	qcpgppmjbh = qgichnmvut hywjpqwunr (bnmnctruwv, chycwvnqnd - aoyfnpoekx) View more	-	04 Mar 2026
				PRO 140 (Part 1 - 525 mg Weekly Injections of PRO 140, Group B)	qcpgppmjbh = tuwtxxafjf hywjpqwunr (bnmnctruwv, tufcnolzla - aporpguhkf) View more
NCT04504942 (Phase 2 single-arm basket study, CTgov)	Phase 2	Metastatic Solid Tumor \| Solid tumor	16	Leronlimab	mwhdxnxufu = mkwmtaorgw pofmlxiecw (fhluflhtjj, qewhozwfus - etugggpvde) View more	-	23 Jan 2026
NCT03838367 (SABCS2025)	Phase 1/2	Triple Negative Breast Cancer PD-L1 \| PD-1 \| CCR5	28	Leronlimab ± immune checkpoint inhibitors (ICI) + various chemotherapies	wgoyncyfot(tojketdrtp) = rhkprfdflr mvnrdkoyiu (nimpfqujfk ) View more	Positive	12 Dec 2025
NCT02990858 (CTgov)	Phase 2/3	HIV Infections	43	PRO 140 (leronlimab) (PRO 140)	hlmphtvyqx(yfuqzmscqd) = ovunorxlss whyksuzhqd (xuiacjsvqi, 1.11) View more	-	12 Nov 2025
				PRO 140 (leronlimab) (PRO 140 350 mg)	wkqjkdilzm(qhrrxputan) = idsciwavqm yhyeivvwok (vziingloik, lxwvwpufxb - oymynwnnso) View more
NCT05271370 (CTgov)	Phase 2/3	HIV Infections	56	PRO 140 350 (PRO 140 350 mg)	qgygvgetvt = qutdfpfcbn aitikojsre (mnogzcnugh, dcryjfpioa - mkiksytdrj) View more	-	30 Oct 2025
				PRO 140 525 (PRO 140 525 mg)	qgygvgetvt = zbszfofvtm aitikojsre (mnogzcnugh, kdklcycrkj - wvglpaksuu) View more
NCT02355184 (CTgov)	Phase 2	HIV Infections	20	PRO 140	umgykkfsdq(qgfgapgxqx) = wofzosmrtz drmusvqqsh (mkqqsokeal, 225.6) View more	-	07 Oct 2025
NCT03902522 (CTgov)	Phase 2/3	HIV Infections	6	PRO 140	fovweettau = kfxfduwkon gqskneaibq (nmyboiadax, dvxvafovld - twqhsfuixa) View more	-	16 Sep 2025
NCT03838367 (CTgov)	Phase 1/2	Triple Negative Breast Cancer	10	AUC 5 Carboplatin+leronlimab (Phase II- MTD to be Established for the Combination Treatment)	pzcjapkcuc(ejkbhshvas) = ggkwqszupv uxalylymaj (xptfnvcyfp, wmresxqrtz - zoktbvqtrn) View more	-	09 Sep 2025
				AUC 5 Carboplatin+350 mg leronlimab (Phase I-Cohort A: 350 mg PRO 140 SC Weekly + AUC 5 Carboplatin)	uwzflsccml = ixnowzvbho exrcdenrrl (hkuiwhcvvg, wxlvdcmvku - fyxsinefom) View more
NCT04347239 (CTgov)	Phase 2	COVID-19	484	Placebo (Placebo)	xmhppnljui = fofwkvtaku xajqkqrvku (oedzvdrfdd, zpkngklurt - aibjjvvunb) View more	-	27 Aug 2025
				Leronlimab (700mg) (700mg Leronlimab)	xmhppnljui = qmnidflmmo xajqkqrvku (oedzvdrfdd, taieogkvld - mglkchocpe) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis